SK Biopharmaceuticals signs KRW 63.31 billion drug supply deal with SK Life Science Inc

Bitget2026/09/23 05:50

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

SK Biopharmaceuticals signed a drug supply contract valued at KRW 63.31 billion to supply cenobamate (XCOPRI) for US sales.
Counterparty SK Life Science is its US subsidiary, making the deal an internal transaction not recognized as consolidated revenue.
Contract value reflects USD 46.55 million converted at KRW 1,360 per USD, excluding VAT.
Order date was Sept. 23, 2026; contract runs Sept. 23-25, 2026; payment due within 120 days of delivery.
Deal equals 9% of 2025 consolidated revenue of KRW 706.74 billion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SK Biopharmaceuticals Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20260923800342), on September 23, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

SK Biopharmaceuticals signs KRW 63.31 billion drug supply deal with SK Life Science Inc

You may also like

Crypto prices